Related Experiment Video

Updated: Feb 26, 2026

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.8K

Drug development against the hippo pathway in mesothelioma

Gavitt A Woodard1, Yi-Lin Yang1, Liang You1

  • 1Department of Surgery, University of California, San Francisco, USA.

Translational Lung Cancer Research
|July 18, 2017
PubMed

Insights

Malignant pleural mesothelioma (MPM) treatments are improving. Novel small molecule YAP inhibitors target cancer stem cells, showing promise as effective chemotherapy drugs for MPM.

Area of Science:

  • Oncology
  • Cancer Stem Cell Biology
  • Molecular Biology

Background:

  • Malignant pleural mesothelioma (MPM) treatment advances have been limited.
  • Conventional chemotherapy fails to address cancer stem cells, leading to resistance and recurrence.
  • The Hippo pathway, involving NF2 (Neurofibromatosis 2) and YAP (Yes-associated protein 1) oncogenes, is crucial in MPM.

Purpose of the Study:

  • To investigate the role of the Hippo-YAP pathway in MPM.
  • To identify novel therapeutic targets for MPM.
  • To evaluate the potential of YAP inhibitors as MPM chemotherapy.

Main Methods:

  • Analysis of NF2 mutations in MPM.
  • Assessment of YAP activity in MPM.
  • Preclinical studies of small molecule YAP inhibitors.

Main Results:

  • NF2 is mutated in 40-50% of MPM cases.
  • YAP is constitutively active in over 70% of MPM.
  • Small molecule YAP inhibitors demonstrate promising preclinical results.

Conclusions:

  • The YAP/TEAD complex is a key therapeutic target in MPM.
  • YAP inhibitors represent a promising new avenue for MPM chemotherapy.
  • Targeting cancer stem cell pathways offers a novel strategy for treating MPM.
Keywords:
Cancer stem cellNeurofibromatosis type 2 (NF2)Yes-associated protein (YAP)small molecule inhibitors

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

11.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
10.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K